Eaton Financial Holdings’s Esperion Therapeutics ESPR Stock Holding History

Eaton Financial Holdings’s Portfolio ESPR Stock Details ESPR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$90.9K	Sell	28,774 -17,821	-38%	-$49.9K	0.03%	131
2026 Q1	$128K	Hold	46,595	–	–	0.04%	122
2025 Q4	$172K	Buy	46,595 +4,000	+9%	+$12.9K	0.05%	131
2025 Q3	$113K	Buy	+42,595	New	+$82.4K	0.03%	121
2025 Q2	–	Sell	-49,530	Closed	-$71.3K	–	117
2025 Q1	$71.3K	Buy	49,530 +5,500	+12%	+$10.1K	0.03%	63
2024 Q4	$96.9K	Hold	44,030	–	–	0.04%	63
2024 Q3	$72.7K	Buy	+44,030	New	+$88.9K	0.03%	62
2024 Q1	$91.2K	Hold	34,030	–	–	0.05%	60
2023 Q4	$102K	Buy	+34,030	New	+$44.1K	0.02%	150

Other funds holding ESPR

GCL

Glazer Capital LLC New York $4.07B AUM 78.71% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Trium Capital London, United Kingdom $163M AUM 45.8% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

AQR Arbitrage Greenwich, Connecticut $7.02B AUM 31.58% 1-Year Est. Return

OBAM

ODDO BHF Asset Management Paris, France $2.16B AUM 43.32% 1-Year Est. Return

Eaton Financial Holdings's ESPR Position: Q2 2026 in Review

Eaton Financial Holdings reduced its Esperion Therapeutics (ESPR) stake by 38% in Q2 2026, selling an estimated $49.9K and leaving 28,774 shares worth $90.9K. The position accounts for 0.03% of the portfolio, ranked #131.

Eaton Financial Holdings first reported a position in ESPR in Q4 2023 and has held it in 9 quarters since. The position peaked at $172K in Q4 2025. 191 funds tracked by Wall St. Rank hold ESPR as of Q2 2026.

Eaton Financial Holdings held 28,774 shares of Esperion Therapeutics worth $90.9K as of Q2 2026.
Eaton Financial Holdings sold 17,821 Esperion Therapeutics shares in Q2 2026, an estimated $49.9K.
Esperion Therapeutics made up 0.03% of Eaton Financial Holdings's portfolio in Q2 2026, its #131 holding.
Eaton Financial Holdings first reported a position in Esperion Therapeutics in Q4 2023 and has held it in 9 quarters since.
Eaton Financial Holdings's Esperion Therapeutics position peaked at $172K in Q4 2025.
191 funds tracked by Wall St. Rank held Esperion Therapeutics as of Q2 2026.

Based on Eaton Financial Holdings's 13F filing for Q2 2026, filed 5 Aug 2026.